Login to Your Account



Company Ripe For Takeover?

Celgene's Revlimid Looks Strong In Bid To Grab MDS Market Share

By Randall Osborne


Monday, September 20, 2004
With profitability reached last year, a rise in its stock price of more than 25 percent since the start of 2004, the FDA reviewing Thalomid for blood cancer and a 2-for-1 stock split due for shareholders next month, Celgene Corp. is sitting pretty - and also could be quite a takeover candidate for a deep-pocketed pharma company looking for a good cancer story. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription